A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme, NCT01752491 (2024)

Government Record · University of Iowa (principal investigator Joseph J. Cullen), registered with ClinicalTrials.gov · December 20, 2024

University of Iowa (principal investigator Joseph J. Cullen), 2024-12-20: NCI-supported phase 1 trial of high-dose intravenous ascorbate added to standard chemoradiation in glioblastoma, enrolling 13 participants, started April 2013, completed November 2019.

This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma multiforme (GBM).

Study Overview, unpaginated

University of Iowa (principal investigator Joseph J. Cullen), 2024-12-20: NCI-supported phase 1 trial of high-dose intravenous ascorbate added to standard chemoradiation in glioblastoma, enrolling 13 participants, started April 2013, completed November 2019. Funding evidence is explicit in the record: other study IDs list 'P30CA086862 (U.S. NIH Grant/Contract)' and 'U01CA140206 (U.S. NIH Grant/Contract)' – both NCI mechanisms – with the university as sponsor. Maker: pharmaceutical ascorbate, no commercial sponsor. Comparator: none (single-arm phase 1, safety). Conflicts: none disclosed. Demonstrates that NCI money does fund IV vitamin C trials.